Maita Karla C, Avila Francisco R, Torres-Guzman Ricardo A, Garcia John P, Eldaly Abdullah S, Palmieri Luiza, Emam Omar S, Ho Olivia, Forte Antonio J
Division of Plastic Surgery, Mayo Clinic, Jacksonville, Florida, USA.
J Clin Transl Res. 2022 Nov 9;8(6):488-498. eCollection 2022 Dec 29.
Wound healing is a complex process comprised of several distinct phases. An imbalance in any of the stages creates a chronic wound with the potential to cause life-threatening complications for patients. Chitosan (CS) is a biopolymer that has shown to positively impact the different healing phases. This systematic review aimed to evaluate the anti-inflammatory and immunomodulatory properties of CS-based wound therapy for the skin healing process after an injury.
A systematic review was conducted in November 2021 following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The PubMed, Embase, Google Scholar, and Cochrane online databases were queried to capture all publications in the past 10 years that investigated the CS effects on inflammation and immune reaction.
A total of 234 studies were screened after removing duplicates and 14 articles fulfilled our inclusion and exclusion criteria. In the studies, CS was combined with a wide range of products. One clinical trial was found that treated patients with diabetic foot ulcers. All animal models in the studies used a full-thickness skin wound to test the effectiveness of CS in the healing process. Decreased pro-inflammatory cytokine levels, a shortened inflammatory phase and accelerated wound closure was observed in all of the studies.
CS proved to be a feasible, versatile, and multifaceted biomaterial that enhances the biological response to a skin injury. When combined with other products, its potential to boost the healing process through regulation of the inflammatory and cellular activity is increased.
Although few clinical trials have been completed, CS has become an excellent alternative to modulate the local inflammatory response promoting wound healing. Especially in patients with associated comorbidities that affect the typical resolution of skin healing, such as diabetes and vascular insufficiency. Therefore, using bioactive wound dressings based on CS combined with nanoparticles, growth factors, lived cells, or medications released in a controlled manner positively impacts patient life by shorting the wound healing process.
伤口愈合是一个由几个不同阶段组成的复杂过程。任何一个阶段的失衡都会导致慢性伤口,有可能给患者带来危及生命的并发症。壳聚糖(CS)是一种生物聚合物,已显示出对不同愈合阶段有积极影响。本系统评价旨在评估基于壳聚糖的伤口治疗对损伤后皮肤愈合过程的抗炎和免疫调节特性。
2021年11月按照系统评价和Meta分析的首选报告项目指南进行了一项系统评价。查询了PubMed、Embase、谷歌学术和Cochrane在线数据库,以获取过去10年中所有研究壳聚糖对炎症和免疫反应影响的出版物。
去除重复项后共筛选出234项研究,14篇文章符合我们的纳入和排除标准。在这些研究中,壳聚糖与多种产品结合使用。发现一项临床试验治疗了糖尿病足溃疡患者。研究中的所有动物模型都使用全层皮肤伤口来测试壳聚糖在愈合过程中的有效性。在所有研究中均观察到促炎细胞因子水平降低、炎症期缩短和伤口闭合加速。
壳聚糖被证明是一种可行、通用且多方面的生物材料,可增强对皮肤损伤的生物学反应。当与其他产品结合使用时,其通过调节炎症和细胞活性促进愈合过程的潜力会增加。
尽管完成的临床试验很少,但壳聚糖已成为调节局部炎症反应促进伤口愈合的极佳替代品。特别是在患有影响皮肤愈合典型恢复的相关合并症的患者中,如糖尿病和血管功能不全。因此,使用基于壳聚糖并与纳米颗粒、生长因子、活细胞或可控释放药物相结合的生物活性伤口敷料,通过缩短伤口愈合过程对患者生活产生积极影响。